Teva Pharmaceuticals presented data at the 2025 Psych Congress Elevate Annual Meeting showcasing positive real-world results for UZEDY (risperidone)...

NurExone Biologic Inc. announced that Professor Nahshon Knoller will present at the American Spinal Injury Association (ASIA) annual meeting....

PolyPid Ltd., a late-stage biopharmaceutical company, is preparing to release topline results from its phase 3 SHIELD II trial...

Syncromune has dosed the first patient in its LEGION-100 Phase 2a trial for SYNC-T Therapy SV-102. This trial focuses...

Regeneron and Sanofi announced Phase 3 trial results for itepekimab, a potential COPD treatment for former smokers. AERIFY-1 met...

In this conversation with Jeffrey Sorenson, CEO at Yunu, we explore the transformative potential of treating imaging data as...

The FDA granted Fast Track designation to Teva Pharmaceutical’s investigational anti-IL-15 antibody, TEV-53408, for celiac disease treatment. This designation...

Vaccinex announced new data on pepinemab’s mechanism of action in enhancing immune responses to checkpoint therapies in neoadjuvant head...

BioXcel Therapeutics announced positive safety results from the first 115 patients in its SERENITY At-Home Phase 3 trial of...

Spur Therapeutics announced preclinical data for FLT201, its gene therapy candidate for Gaucher disease, published in Molecular Therapy. The...